Abbreviations and Acronyms:MELD (model for end-stage liver disease), OR (odds ratio), PPI (proton pump inhibitor), SBP (spontaneous bacterial peritonitis)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Burden of liver disease in the United States: summary of a workshop.Hepatology. 2002; 36: 227-242
- Underestimation of liver-related mortality in the United States.Gastroenterology. 2013; 145 (e371-e372): 375-382
- Immune dysfunction and infections in patients with cirrhosis.Clin Gastroenterol Hepatol. 2011; 9: 727-738
- Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.Gastroenterology. 2010; 139 (1256.e1241-e1245): 1246-1256
- Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States.Aliment Pharmacol Ther. 2014; 40: 105-112
- Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience.Hepatology. 2012; 56: 2328-2335
- Spontaneous bacterial peritonitis—in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998.Am J Gastroenterol. 2001; 96: 1232-1236
- Management of adult patients with ascites due to cirrhosis.Hepatology. 2004; 39: 841-856
- Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis.Am J Gastroenterol. 2009; 104 (quiz 1002): 993-1001
- Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis.Gastroenterology. 2007; 133: 818-824
- Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.J Hepatol. 2008; 48: 774-779
- Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial.J Hepatol. 1998; 29: 430-436
- Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.Hepatology. 1997; 25: 532-536
- Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis.Clin Gastroenterol Hepatol. 2009; 7: 487-493
- A model to predict survival in patients with end-stage liver disease.Hepatology. 2001; 33: 464-470
- Association of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascites.Am J Gastroenterol. 2009; 104: 1130-1134
- Predictors of fifty days in-hospital mortality in decompensated cirrhosis patients with spontaneous bacterial peritonitis.World J Hepatol. 2016; 8: 566-572
- Prediction of spontaneous bacterial peritonitis in cirrhotic ascites by a simple scoring system.Scand J Gastroenterol. 2014; 49: 595-603
- Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.Hepatology. 2012; 55: 1551-1561
- Long-term use of antibiotics and proton pump inhibitors predict development of infections in patients with cirrhosis.Clin Gastroenterol Hepatol. 2015; 13 (e751-e752): 753-759
- Proton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective study.J Hepatol. 2015; 62: 1056-1060
- Appropriate and timely antimicrobial therapy in cirrhotic patients with spontaneous bacterial peritonitis-associated septic shock: a retrospective cohort study.Aliment Pharmacol Ther. 2015; 41: 747-757
- Bacterial and fungal infections after liver transplantation: an analysis of 284 patients.Hepatology. 1995; 21: 1328-1336
- Early liver transplantation for severe alcoholic hepatitis.N Engl J Med. 2011; 365: 1790-1800
Grant Support: This study was supported by a faculty development grant from the American College of Gastroenterology to Dr Singal.
Potential Competing Interests: The authors report no competing interests.
Data Previously Presented: These data were presented as an abstract at the 2018 American Association for the Study of Liver Diseases meeting in San Francisco, CA, on November 9-13, 2018.